NCT07281820 FRAME - Implementation of a PRO Measure to Inform Patient-Centered Survivorship Care in Oncology Outpatient Visits
| NCT ID | NCT07281820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vejle Hospital |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
FRAME is a patient-centered survivorship care model embedded in routine oncology visits. It consists of: (1) a pre-visit patient-reported questionnaire (FRAME-PRO), (2) a clinician-patient dialogue guided by the responses, and (3) a tailored management plan including stepped-care referrals (general practitioner and municipality; oncology department supportive services; specialized late-effects clinics). The implementation is evaluated with the RE-AIM framework supplemented by Proctor implementation outcomes. Data sources include the "Mit Sygehus" app, departmental registries, purpose-built questionnaires, fidelity checklists, and qualitative interviews with clinicians, patients, and informal caregivers.
Eligibility Criteria
Inclusion Criteria: \- All oncologists conducting outpatient visits at the Department of Oncology, Vejle Hospital during the study period. Exclusion Criteria: \- None. Participants for interviews: * A purposive sample of patients, informal caregivers, and clinicians approached ≥6 months after launch * written and verbally informed consent.
Contact & Investigator
Torben F Hansen, Dr. Med.
STUDY DIRECTOR
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark
Frequently Asked Questions
Who can join the NCT07281820 clinical trial?
This trial is open to participants of all sexes, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07281820 currently recruiting?
Yes, NCT07281820 is actively recruiting participants. Contact the research team at JOHANNE.DAM.LYHNE@RSYD.DK for enrollment information.
Where is the NCT07281820 trial being conducted?
This trial is being conducted at Vejle, Denmark.
Who is sponsoring the NCT07281820 clinical trial?
NCT07281820 is sponsored by Vejle Hospital. The principal investigator is Torben F Hansen, Dr. Med. at Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.